US Patent Issued to BeOne Medicines I on Oct. 28 for "Pyrrolo[2,3-bpyrazines as HPK1 inhibitor and the use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,534, issued on Oct. 28, was assigned to BeOne Medicines I GmbH (Basel, Switzerland).

"Pyrrolo[2,3-bpyrazines as HPK1 inhibitor and the use thereof" was invented by Jing Li (Beijing), Zhiwei Wang (Beijing) and Sanjia Xu (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein."

The patent was filed on July 3, 2020, under Application No. 17/623,732.

*For further informa...